Peptide‐MHC class I stability is a better predictor than peptide affinity of CTL immunogenicity
暂无分享,去创建一个
Morten Nielsen | Søren Buus | Mikkel Harndahl | M. Nielsen | G. Røder | S. Buus | M. Harndahl | M. Rasmussen | Michael Rasmussen | Gustav Roder | Ida Dalgaard Pedersen | Mikael Sørensen | Mikael S. Sørensen | Ida Dalgaard Pedersen | Morten Nielsen | Ida Dalgaard Pedersen | Mikael Sørensen
[1] S Brunak,et al. Sensitive quantitative predictions of peptide-MHC binding by a 'Query by Committee' artificial neural network approach. , 2003, Tissue antigens.
[2] J. McCluskey,et al. The impact of HLA‐B micropolymorphism outside primary peptide anchor pockets on the CTL response to CMV , 2007, European journal of immunology.
[3] D. Margulies,et al. Measuring interactions of MHC class I molecules using surface plasmon resonance. , 1995, Journal of immunological methods.
[4] Bjoern Peters,et al. A Quantitative Analysis of the Variables Affecting the Repertoire of T Cell Specificities Recognized after Vaccinia Virus Infection1 , 2007, The Journal of Immunology.
[5] P. van Endert,et al. Secondary anchor polymorphism in the HA-1 minor histocompatibility antigen critically affects MHC stability and TCR recognition , 2009, Proceedings of the National Academy of Sciences.
[6] J. Frelinger,et al. Amino-terminal alteration of the HLA-A*0201-restricted human immunodeficiency virus pol peptide increases complex stability and in vitro immunogenicity. , 1995, Proceedings of the National Academy of Sciences of the United States of America.
[7] Francisco A. Chaves,et al. The relationship between immunodominance, DM editing, and the kinetic stability of MHC class II:peptide complexes , 2005, Immunological reviews.
[8] A. Canella,et al. Selective amino acid substitutions of a subdominant Epstein‐Barr virus LMP2‐derived epitope increase HLA/peptide complex stability and immunogenicity: implications for immunotherapy of Epstein‐Barr virus‐associated malignancies , 1999, European journal of immunology.
[9] Søren Buus,et al. Real-time, high-throughput measurements of peptide-MHC-I dissociation using a scintillation proximity assay. , 2011, Journal of immunological methods.
[10] A. Vitiello,et al. The relationship between class I binding affinity and immunogenicity of potential cytotoxic T cell epitopes. , 1994, Journal of immunology.
[11] J. Yewdell,et al. Confronting complexity: real-world immunodominance in antiviral CD8+ T cell responses. , 2006, Immunity.
[12] Morten Nielsen,et al. CTL epitopes for influenza A including the H5N1 bird flu; genome-, pathogen-, and HLA-wide screening. , 2007, Vaccine.
[13] Morten Nielsen,et al. NetMHC-3.0: accurate web accessible predictions of human, mouse and monkey MHC class I affinities for peptides of length 8–11 , 2008, Nucleic Acids Res..
[14] D. Margulies,et al. Direct detection of major histocompatibility complex class I binding to antigenic peptides using surface plasmon resonance. Peptide immobilization and characterization of binding specificity. , 1993, The Journal of biological chemistry.
[15] B. Baker,et al. Thermodynamic and kinetic analysis of a peptide-class I MHC interaction highlights the noncovalent nature and conformational dynamics of the class I heterotrimer. , 2003, Biochemistry.
[16] U. Grohmann,et al. Immunogenicity of tumor peptides: importance of peptide length and stability of peptide/MHC class II complex , 1999, Cancer Immunology, Immunotherapy.
[17] Francisco A. Chaves,et al. The kinetic stability of MHC class II:peptide complexes is a key parameter that dictates immunodominance. , 2005, Immunity.
[18] C. Sylvester-Hvid,et al. One-Pot, Mix-and-Read Peptide-MHC Tetramers , 2008, PloS one.
[19] Yuzhang Wu,et al. A naturally processed epitope on rotavirus VP7 glycoprotein recognized by HLA-A2.1-restricted cytotoxic CD8+ T cells. , 2009, Viral immunology.
[20] J. Yewdell,et al. Immunodominance in major histocompatibility complex class I-restricted T lymphocyte responses. , 1999, Annual review of immunology.
[21] A. Rickinson,et al. HLA-B27 subtype polymorphism and CTL epitope choice: studies with EBV peptides link immunogenicity with stability of the B27:peptide complex. , 1998, Journal of immunology.
[22] J. Drijfhout,et al. Steric Hindrance and Fast Dissociation Explain the Lack of Immunogenicity of the Minor Histocompatibility HA-1Arg Null Allele 1 , 2009, The Journal of Immunology.
[23] J. Yewdell,et al. Cut and trim: generating MHC class I peptide ligands. , 2001, Current opinion in immunology.
[24] J. Yewdell,et al. High Peptide Affinity for MHC Class I does not Correlate with Immunodominance , 1999, Scandinavian journal of immunology.
[25] D. Busch,et al. MHC class I/peptide stability: implications for immunodominance, in vitro proliferation, and diversity of responding CTL. , 1998, Journal of immunology.
[26] O. Lund,et al. HLA Class I Binding 9mer Peptides from Influenza A Virus Induce CD4+ T Cell Responses , 2010, PloS one.
[27] C. Sylvester-Hvid,et al. Purification of correctly oxidized MHC class I heavy‐chain molecules under denaturing conditions: A novel strategy exploiting disulfide assisted protein folding , 2003, Protein science : a publication of the Protein Society.
[28] Søren Brunak,et al. Selecting Informative Data for Developing Peptide-MHC Binding Predictors Using a Query by Committee Approach , 2003, Neural Computation.
[29] R. Offringa,et al. Design of agonistic altered peptides for the robust induction of CTL directed towards H-2Db in complex with the melanoma-associated epitope gp100. , 2009, Cancer research.
[30] K. Parker,et al. The beta 2-microglobulin dissociation rate is an accurate measure of the stability of MHC class I heterotrimers and depends on which peptide is bound. , 1992, Journal of immunology.
[31] S Brunak,et al. SARS CTL Vaccine Candidates — HLA Supertype, Genome‐Wide Scanning and Biochemical Validation , 2004, Tissue antigens.
[32] Søren Buus,et al. A quantitative assay to measure the interaction between immunogenic peptides and purified class I major histocompatibility complex molecules , 1994, European journal of immunology.
[33] F. Greenwood,et al. Preparation of Iodine-131 Labelled Human Growth Hormone of High Specific Activity , 1962, Nature.
[34] C. Sylvester-Hvid,et al. Efficient assembly of recombinant major histocompatibility complex class I molecules with preformed disulfide bonds , 2001, European journal of immunology.
[35] S. H. van der Burg,et al. Immunogenicity of peptides bound to MHC class I molecules depends on the MHC-peptide complex stability. , 1996, Journal of immunology.
[36] H. Grey,et al. Free ligand-induced dissociation of MHC-antigen complexes. , 1991, Journal of immunology.
[37] Hidde L. Ploegh,et al. Peptide selection by MHC class I molecules , 1991, Nature.
[38] Wilfried Bardet,et al. Real-time measurement of in vitro peptide binding to soluble HLA-A*0201 by fluorescence polarization. , 2004, Biochemistry.
[39] O. Lund,et al. novel sequence representations Reliable prediction of T-cell epitopes using neural networks with , 2003 .
[40] K. Heeg,et al. In vivo CTL induction with point-substituted ovalbumin peptides: immunogenicity correlates with peptide-induced MHC class I stability. , 1995, Vaccine.
[41] A. Cope,et al. Relationship between kinetic stability and immunogenicity of HLA‐DR4/peptide complexes , 2002, European journal of immunology.
[42] O. Lund,et al. NetMHCpan, a Method for Quantitative Predictions of Peptide Binding to Any HLA-A and -B Locus Protein of Known Sequence , 2007, PloS one.
[43] M. Nielsen,et al. Peptide Binding to HLA Class I Molecules: Homogenous, High-Throughput Screening, and Affinity Assays , 2009, Journal of biomolecular screening.
[44] A Sette,et al. The relation between major histocompatibility complex (MHC) restriction and the capacity of Ia to bind immunogenic peptides , 1987, Science.
[45] R. Tisch,et al. Dendritic cell vaccination induces cross-reactive cytotoxic T lymphocytes specific for wild-type and natural variant human immunodeficiency virus type 1 epitopes in HLA-A*0201/Kb transgenic mice. , 2001, Clinical immunology.
[46] J. Sidney,et al. Improved Immunogenicity of an Immunodominant Epitope of the Her-2/neu Protooncogene by Alterations of MHC Contact Residues1 , 2004, The Journal of Immunology.
[47] D Rognan,et al. Use of fluorescence polarization to monitor MHC-peptide interactions in solution. , 2001, Journal of immunological methods.